Vanguard Group Inc Kymera Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,619,848 shares of KYMR stock, worth $224 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,619,848
Previous 5,231,392
7.43%
Holding current value
$224 Million
Previous $143 Million
71.28%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding KYMR
# of Institutions
217Shares Held
72.2MCall Options Held
178KPut Options Held
64.6K-
Price T Rowe Associates Inc Baltimore, MD6.86MShares$273 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6.65MShares$265 Million2.94% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.56MShares$261 Million5.22% of portfolio
-
Bvf Inc San Francisco, CA5.5MShares$219 Million9.44% of portfolio
-
Wellington Management Group LLP Boston, MA5.37MShares$214 Million0.04% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.18B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...